Companies › Dyne Therapeutics
2 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 1; Neurology; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| zeleciment basivarsen (DYNE-101) antisense oligonucleotide targeting DMPK mRNA | DMPK | Phase 3 | Myotonic Dystrophy Type 1 (DM1) | Jul 2028 |
| Zeleciment Rostudirsen (DYNE-251) Antisense oligonucleotide for exon 51 skipping | DMD | Phase 3 | Duchenne Muscular Dystrophy (DMD) | Dec 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07486934 | zeleciment basivarsen (DYNE-101) | Phase 3 | Myotonic Dystrophy Type 1 (DM1) | Neurology | Jul 2028 |
| NCT05481879 | zeleciment basivarsen (DYNE-101) | Phase 1 | Myotonic Dystrophy Type 1 (DM1) | Neurology | Jul 2029 |
| NCT07608432 | Zeleciment Rostudirsen (DYNE-251) | Phase 3 | Duchenne Muscular Dystrophy (DMD) | Neurology | Dec 2030 |
| NCT05524883 | Zeleciment Rostudirsen (DYNE-251) | Phase 1 | Duchenne Muscular Dystrophy (DMD) | Neurology | Sep 2031 |
Cash and short-term investments of $1.1bn on 2026-09-30; operating cash outflow about $607m a year; runway about 22 months at that burn, to Aug 2028; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 14 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Capricor Stoke Therapeutics REGENXBIO Nippon Shinyaku Alasht Pharmed
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.